Citigroup’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
Citigroup's RXRX Position: Q3 2026 in Review
Citigroup reduced its Recursion Pharmaceuticals (RXRX) stake by 58% in Q3 2026, selling an estimated $1.7M and leaving 363,644 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3031.
Citigroup first reported a position in RXRX in Q2 2021 and has held it in 22 quarters since. The position peaked at $7.99M in Q1 2024. 353 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.
- Citigroup held 363,644 shares of Recursion Pharmaceuticals worth $1.5M as of Q3 2026.
- Citigroup sold 500,759 Recursion Pharmaceuticals shares in Q3 2026, an estimated $1.7M.
- Recursion Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3031 holding.
- Citigroup first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 22 quarters since.
- Citigroup's Recursion Pharmaceuticals position peaked at $7.99M in Q1 2024.
- 353 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.